Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction Notice: Survodutide for Adults with Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease: Findings from the SYNCHRONIZE-MASLD Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

  • By

  • Lee M. Kaplan

  • Elena Startseva

  • Carel W. le Roux

  • Sean Wharton

  • Biykem Bozkurt

  • Daniel F. Mazo

  • Jessica von Schlippenbach

  • Sandra González Maldonado

  • Samina Ajaz Hussain

  • Guy W. Neff

  • Yaneicy Gonzalez Rojas

  • Charles Smith

  • Ramy Younes

  • Arun J. Sanyal

  • August 25, 2026

Share

Correction Notice: Survodutide for Adults with Obesity and MASLD

Overview

This correction notice addresses several errors in the previously published article regarding the SYNCHRONIZE-MASLD trial. Key amendments include author affiliations and a numerical correction in the treatment-discontinuation frequencies.

Background

The SYNCHRONIZE-MASLD trial aimed to evaluate the efficacy of survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

Data Highlights

No numerical data is presented in the correction notice.

Key Findings

  • Juan M. Pericás and Michael Zimmerman were added to the author list with correct affiliations.
  • Antonio Olveira's name and affiliation were corrected.
  • Rizwana Mohseni's second affiliation was corrected.
  • A numerical typographical error in the treatment-discontinuation frequencies was amended from 72 to 70 for the placebo group.
  • The Extended Data Fig. 5 caption was corrected from 'week 48' to 'week 52.'

Clinical Implications

This correction notice ensures that the scientific community has access to reliable information regarding author attribution and data reporting.

Conclusion

This correction notice details specific amendments made to the original publication.

Related Resources & Content

  1. SYNCHRONIZE-MASLD Investigators, Nature Medicine, 2026 -- Correction Notice: Survodutide for Adults with Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease
  2. MDSpire News — Investigational Drug Shows Potentialin Phase 3 Obesity Trial
  3. MDSpire News — Global Consensus Streamlines MASLD/MASH Care
  4. Journal of Gastroenterology — Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026
  5. FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’ | FDA
  6. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial | Nature Medicine
  7. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine
  8. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis - PubMed
  9. Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis - PubMed
  10. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary - PMC

Original Source(s)

Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

  • by Lee M. Kaplan, Elena Startseva, Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Daniel F. Mazo, Jessica von Schlippenbach, Sandra González Maldonado, Samina Ajaz Hussain, Guy W. Neff, Yaneicy Gonzalez Rojas, Charles Smith, Ramy Younes, Arun J. Sanyal

  • August 25, 2026

Related Content

Documented risk-based antithrombotic management and 30-day outcomes after endoscopic hemostasis for non-variceal upper gastrointestinal bleeding: a retrospective cohort study

Outcomes of emergent hiatal hernia repair: does specialty matter?

Rates of hospitalization pre- and post-total pancreatectomy with islet autotransplantation for patients with pancreatitis